Search results for " OUTCOME"

showing 10 items of 4574 documents

PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation

2019

OBJECTIVE: To identify disease-causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and provide targeted replacement therapy. METHODS: We performed genome-wide sequencing, homozygosity mapping, and segregation analysis for novel disease-causing gene discovery. We used circular dichroism to show secondary structure changes and isothermal titration calorimetry to investigate the impact of variants on adenosine triphosphate (ATP) binding. Pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombinant protein, patient-derived fibroblasts, plasma, and erythrocytes. Response to supplementation was measured with clinical validated rating sc…

0301 basic medicineMale[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyLOCAL TRANSLATIONMedizinmedicine.disease_causeDISEASEchemistry.chemical_compound0302 clinical medicinepolineuropathyCinètica enzimàticaGene Regulatory NetworksPyridoxal phosphateChildPyridoxal KinaseAdenosine triphosphate (ATP)Research ArticlesAged 80 and overMutationGene Regulatory NetworkPLASMAAutosomal recessive axonal polyneuropathyDisease gene identificationPyridoxal kinase3. Good healthSettore MED/26 - NEUROLOGIANeuropaties perifèriquesTreatment OutcomePolyneuropathieNeurologyChild PreschoolPyridoxal PhosphateRELIABILITYVitamin B ComplexFemaleLife Sciences & BiomedicinePolyneuropathyHumanResearch ArticleAdultAdolescentPDXKClinical NeurologyCHARCOT-MARIE-TOOTHCHARCOT-MARIE-TOOTH CMT NEUROPATHY SCORE LOCAL TRANSLATION DISEASE RELIABILITY; MECHANISMS DISCOVERY FRAMEWORK KINASE PLASMAMECHANISMS03 medical and health sciencesPolyneuropathiesAtrophy[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]KINASEmedicineHumansCMT NEUROPATHY SCOREPDXK mutationsPyridoxalDietary SupplementAgedPeripheral neuropathiesScience & Technology[SCCO.NEUR]Cognitive science/NeuroscienceEnzyme kineticsNeurosciencesFRAMEWORKmedicine.diseaseMolecular biology030104 developmental biologychemistryDISCOVERYDietary SupplementsMutationNeurosciences & NeurologyNeurology (clinical)Adenosine triphosphate030217 neurology & neurosurgeryAnnals of Neurology
researchProduct

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

2019

Abstract Background Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. Methods In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-w…

0301 basic medicineMalemedicine.medical_specialtyAbdominal painAdolescentEndocrinology Diabetes and MetabolismGlobotriaosylceramideUrologyRenal function030105 genetics & heredityBiochemistrylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRandomized controlled triallawBiopsyGeneticsmedicineHumansEnzyme Replacement TherapyChildMolecular BiologySkinKidneymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseIsoenzymesmedicine.anatomical_structureTreatment OutcomechemistryChild Preschoolalpha-GalactosidaseFabry Diseasemedicine.symptombusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Effect of nutritional supplementations on physical performance and muscle strength parameters in older people: A systematic review and meta-analysis

2019

Malnutrition plays a role in the development of poor physical performance, frailty and sarcopenia. The use of nutritional supplementations for improving physical performance and muscle strength parameters in older people is unclear. We therefore aimed to summarize the effect of nutritional supplementations compared to placebo on physical performance (i.e. tests more investigating physical function, utilising aerobic capacity & muscle power) and muscle strength (i.e. tests depending on muscle power) outcomes in older people in randomized controlled trials (RCTs). A literature search in major databases was undertaken until the 01st September 2018. Eligible studies were RCTs investigating …

0301 basic medicineMalemedicine.medical_specialtyAgingSarcopeniaNutritional SupplementationPlaceboBiochemistrylaw.inventionPhysical performance03 medical and health sciencesA systematic review and meta-analysis.- Ageing research reviews cilt.51 ss.48-54 2019 [VERONESE N. STUBBS B. PUNZI L. Soysal P. INCALZI R. SALLER A. MAGGI S. -Effect of nutritional supplementations on physical performance and muscle strength parameters in older people]0302 clinical medicineRandomized controlled triallawmedicineHumansMolecular BiologyAgedRandomized Controlled Trials as TopicNutritionAged 80 and overHand Strengthbusiness.industryMuscle strengthPhysical Functional Performancemedicine.diseaseConfidence intervalMalnutritionMeta-analysis030104 developmental biologyTreatment OutcomeNeurologyPhysical performanceSarcopeniaMeta-analysisDietary SupplementsPhysical therapyFemalebusiness030217 neurology & neurosurgeryBiotechnology
researchProduct

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or l…

2019

Abstract Background Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. The first-in-class monoclonal antibody, zolbetuximab (formerly known as IMAB362), binds to CLDN18.2 and can induce immune-mediated lysis of CLDN18.2-positive cells. Patients and methods Patients with advanced gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinomas with moderate-to-strong CLDN18.2 expression in ≥50% of tumour cells received zolbetuximab intravenously every 2 weeks for five planned infusions. At least three patients …

0301 basic medicineMalemedicine.medical_specialtyCLDN18.2Drug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsNauseagastro-oesophageal junction adenocarcinomaMedizinAdenocarcinomaGastroenterology03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineGastrointestinal TumorsmedicineHumansProgression-free survivalAgedbusiness.industryStomachgastric cancerCancerAntibodies MonoclonalHematologyOriginal ArticlesMiddle Agedmedicine.diseaseddc:IMAB362030104 developmental biologymedicine.anatomical_structureTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisCohortVomitingAdenocarcinomaFemaleEsophagogastric Junctionmedicine.symptomzolbetuximabNeoplasm Recurrence Localbusiness
researchProduct

Effects of DBS in parkinsonian patients depend on the structural integrity of frontal cortex

2017

AbstractWhile deep brain stimulation of the subthalamic nucleus (STN-DBS) has evolved to an evidence-based standard treatment for Parkinson’s disease (PD), the targeted cerebral networks are poorly described and no objective predictors for the postoperative clinical response exist. To elucidate the systemic mechanisms of DBS, we analysed cerebral grey matter properties using cortical thickness measurements and addressed the dependence of structural integrity on clinical outcome. Thirty one patients with idiopathic PD without dementia (23 males, age: 63.4 ± 9.3, Hoehn and Yahr: 3.5 ± 0.8) were selected for DBS treatment. The patients underwent whole-brain preoperative T1 MR-Imaging at 3 T. G…

0301 basic medicineMalemedicine.medical_specialtyDeep brain stimulationmedicine.medical_treatmentDeep Brain StimulationStimulationGrey matterMotor ActivityArticleWorkflow03 medical and health sciences0302 clinical medicineSubthalamic NucleusInternal medicinemedicineDementiaHumansAgedMultidisciplinarybusiness.industryStandard treatmentStructural integrityParkinson DiseaseMiddle Agedmedicine.diseaseMagnetic Resonance Imagingnervous system diseasesFrontal LobeSubthalamic nucleus030104 developmental biologymedicine.anatomical_structuresurgical procedures operativeTreatment OutcomeFrontal lobenervous systemCardiologyFemalebusinesstherapeutics030217 neurology & neurosurgeryScientific Reports
researchProduct

Pulmonary Strongyloides stercoralis infection.

2016

0301 basic medicineMalemedicine.medical_specialtyFatal outcomeEndemic DiseasesLung Diseases Parasiticmedicine.medical_treatment030106 microbiologySplenectomyMEDLINEGastroenterologyStrongyloides stercoralis03 medical and health sciencesImmunocompromised Host0302 clinical medicineFatal OutcomeX ray computedGastrectomyStomach NeoplasmsInternal medicineOccupational ExposuremedicineAnimalsHumansAged 80 and overbiologybusiness.industryMediterranean RegionSmokingGeneral Medicinebiology.organism_classificationAgricultural Workers' Diseases030228 respiratory systemSplenectomyStrongyloidiasisGastrectomyOccupational exposureEndemic diseasesbusinessStrongyloides stercoralisTomography X-Ray ComputedArchivos de bronconeumologia
researchProduct

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-…

2019

Abstract Background Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions Our findings support in clinical practice …

0301 basic medicineMalemedicine.medical_specialtyMeta-AnalysiBone Density Conservation Agentmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsBone NeoplasmZoledronic Acidlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansHypocalcaemiaBreastAdverse effectBone Density Conservation AgentsSolid tumorbusiness.industryMortality rateProstateProstatic NeoplasmsAEHematologyBisphosphonateSMRmedicine.diseaseBone metastase030104 developmental biologyZoledronic acidTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisProstatic NeoplasmFemalebusinessBreast Neoplasmmedicine.drugHuman
researchProduct

Effect of chondroitin sulphate on synovitis of knee osteoarthritic patients.

2017

Abstract Objective To evaluate by ultrasonography the effect of chondroitin sulfate (CS) on synovitis in patients with knee osteoarthritis (KOA). To collaborate in the understanding of the biochemical mechanisms involved in the synovial inflammation process. Methods Randomized, single-blind, controlled trial involving 70 patients with primary KOA treated for 6 months with CS or acetaminophen (ACT). Evaluation of KOA status at baseline, 6 weeks, 3 and 6 months included: ultrasonography to assess synovitis (following the OMERACT expertise group definition), visual analogue scale and Lequesne index to measure pain and function, and ELISA to quantify inflammatory mediators in serum and synovial…

0301 basic medicineMalemedicine.medical_specialtyVisual analogue scaleInflammationPilot ProjectsOsteoarthritisGastroenterologylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineSynovitisMedicineSynovial fluidHumansSingle-Blind MethodChondroitin sulfateAcetaminophenAgedPain MeasurementUltrasonography030203 arthritis & rheumatologyAged 80 and overSynovitisbusiness.industryAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesMiddle AgedOsteoarthritis Kneemedicine.diseaseAcetaminophenBiomechanical Phenomena030104 developmental biologyTreatment OutcomechemistryFemalemedicine.symptombusinessBiomarkersmedicine.drugFollow-Up StudiesMedicina clinica
researchProduct

Circulating Irisin Levels in Children With GH Deficiency Before and After 1 Year of GH Treatment.

2018

Abstract Purpose To evaluate circulating irisin levels in children with GH deficiency (GHD) and any relation with clinical and metabolic parameters. Patients Fifty-four prepubertal children (mean age, 7.4 ± 0.8 years) with idiopathic GHD treated with GH for at least 12 months and 31 healthy short children as control subjects. Methods Body height, body mass index (BMI), waist circumference (WC), IGF-I, HbA1c, lipid profile, fasting and after–oral glucose tolerance test glucose and insulin, insulin sensitivity indices, and irisin levels were evaluated at baseline and after 12 months of GH replacement (GHR). Results At baseline, children with GHD, in addition to having lower growth velocity (P…

0301 basic medicineMalemedicine.medical_specialtyWaistHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical Biochemistry030209 endocrinology & metabolismGrowth hormone receptorBiochemistrySettore MED/13 - EndocrinologiaGrowth hormone deficiencyBody Mass Index03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicinemedicineHumansProspective StudiesInsulin-Like Growth Factor IChildGrowth DisordersGlucose tolerance testmedicine.diagnostic_testbusiness.industryInsulinBiochemistry (medical)medicine.diseaseFibronectins030104 developmental biologyEndocrinologyTreatment OutcomeGrowth HormoneFemaleWaist CircumferenceLipid profilebusinessBody mass indexThe Journal of clinical endocrinology and metabolism
researchProduct

Improvement of Main Cognitive Functions in Patients with Alzheimer's Disease after Treatment with Coconut Oil Enriched Mediterranean Diet: A Pilot St…

2018

BACKGROUND Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder (mainly in women), and new therapies are needed. In this way, ketone bodies are a direct source of cellular energy and can be obtained from coconut oil, postulating that coconut oil could be a new non-pharmacological alternative in AD patients. OBJECTIVE The aim of this study is to detect changes in the main cognitive functions of patients with AD after following a coconut oil enriched Mediterranean diet, and to determine whether there are differences in function of stage or sex. METHODS A prospective, longitudinal, qualitative, analytic, experimental study was carried out in 44 patients with AD, who were r…

0301 basic medicineMalemedicine.medical_specialtyfood.ingredientMediterranean dietDiseaseDiet MediterraneanSeverity of Illness Index03 medical and health sciences0302 clinical medicinefoodCognitionSex FactorsAlzheimer DiseaseMemoryInternal medicineSeverity of illnessmedicineSemantic memoryHumansIn patientLongitudinal StudiesEpisodic memoryQualitative ResearchAgedAged 80 and overbusiness.industryGeneral NeuroscienceCoconut oilfood and beveragesCognitionGeneral MedicinePsychiatry and Mental healthClinical Psychology030104 developmental biologyTreatment OutcomeTime PerceptionCoconut OilFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryJournal of Alzheimer's disease : JAD
researchProduct